[Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
OBJECTIVE
To evaluate the efficacy of strontium-89 (89Sr) in the treatment of painful bone metastases of prostate cancer.


METHODS
A total of 116 patients with painful bone metastases of prostate cancer received bilateral orchiectomy and incretion, followed by intravenous injection of 89Sr at the dose of 1.48-2.22 MBq (40-60 microCi)/kg. The clinical effects were evaluated by follow-up analysis.


RESULTS
After the 89Sr treatment, appetite and sleep were evidently improved in 33.6% and 56.0% of the patients respectively, the applied dose of anodyne reduced in 61.2%, pain alleviated in 83.6%, with an absolute palliation rate of 24.1%. Pain relief started at 3-21 (10.2 +/- 6.5) days and lasted 3-12 (5.3 +/- 2.2) months. Flare ache occurred in 31.9% of the patients. Compared with pre-treatment, the mean score on Karnofsky's performance status (KPS) was 20.0% higher, and the WBC count decreased to 3.0-3.9 x 10(6)/L in 18.1% of the patients. Whole body bone scintigraphy of 53 followed-up patients showed that 39 (73.6%) of them exhibited an obvious decrease in the number of metastases, 10 (18.9% remained in a stabilized state and only 4 (7.5% deteriorated.


CONCLUSIONS
89Sr, capable of inhibiting bone metastasis, palliating pain and improving the quality of life with few adverse effects, can be used as a desirable therapeutic for painful bone metastases of prostate cancer.
Ma
Yu-Bo
YB
Department of Nuclear Medicine, the Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200011, China. myb7802@126.com
Yan
Wei-Li
WL
Dai
Ji-Can
JC
Xu
Feng
F
Yuan
Qi
Q
Shi
He-Hai
HH
D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010148:Intractable Pain / Q000532:radiotherapy; D011471:Prostatic Neoplasms / Q000473:pathology*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D016896:Treatment Outcome
D013326:Strontium Radioisotopes